BEST WEIGHT LOSS INJECTION IN INDIA

Why 'best' is the wrong question

Every article ranking these medicines assumes all patients are interchangeable. They are not. A patient with type 2 diabetes, a patient with PCOS and a patient with neither will each be assessed differently.

The medicine producing the largest average result in a trial is irrelevant if you cannot tolerate the dose required to reach it, or if it is unavailable, or if you cannot sustain the cost for the duration you will need it.

A better question is: which of these is appropriate for my diagnosis, my history and my circumstances? That is what a consultation determines.

Anyone naming a single best injection without knowing your BMI, medications and medical history is guessing.

The molecules available

There are three relevant active molecules rather than a long list of brands, and most confusion comes from brand names attached to the same molecule.

Tirzepatide is a dual agonist, acting on both GIP and GLP-1 receptors. Sold as Mounjaro.

Semaglutide acts on the GLP-1 receptor. Sold as Ozempic, licensed for type 2 diabetes, and as Wegovy, licensed for weight management at a higher maximum dose.

Liraglutide is an older GLP-1 agonist, taken daily rather than weekly, sold as Victoza and Saxenda.

Reported effectiveness

Published trials report average total body weight reductions of roughly 20% at the highest tirzepatide doses over about 72 weeks, and roughly 15% for high-dose semaglutide over about 68 weeks, both alongside lifestyle support.

Liraglutide produces smaller average reductions, in the region of 8%, which reflects both the molecule and its dosing.

These are trial averages with structured support, not guarantees. Roughly a third of participants achieved substantially more than the mean, and a proportion achieved considerably less.

The maximum doses that produced these figures are not tolerated by everyone, which matters when comparing headline numbers.

Patient outcomes from supervised programmes at our clinic, published with consent and with faces obscured for privacy. Individual results vary.

Dosing and convenience

Tirzepatide and semaglutide are once-weekly injections. Liraglutide is daily, which most patients find harder to sustain over months.

All require gradual dose escalation over several months. This is not optional; it is the main determinant of whether you tolerate treatment.

Weekly dosing means one injection to remember and a single weekly rhythm to side effects. Daily dosing spreads effects more evenly but requires far more consistency.

For most patients, weekly is the practical choice unless there is a specific reason otherwise.

Side effect profiles compared

The profiles are broadly similar across all three, because the mechanism is shared: nausea, reduced appetite, constipation, diarrhoea and reflux, strongest after dose increases.

Higher doses generally mean more pronounced early effects, which is one reason the medicine with the largest average result is not automatically the easiest to take.

Serious effects — pancreatitis, gallbladder disease, and the thyroid precaution — apply across the class rather than to one product.

Individual tolerance varies considerably and is only discoverable in practice. Some patients do markedly better on one molecule than another, and switching is a recognised clinical option.

Cost in India

All are priced by strength, so monthly cost rises as the dose escalates. This makes direct comparison harder than it appears, because two patients on the same medicine may pay very different amounts.

Tirzepatide at higher doses is generally the most expensive option. Liraglutide is often cheaper per month but requires daily dosing and delivers smaller average results.

Because treatment often continues for many months, annual cost is the meaningful figure rather than the first month.

A programme should also include consultations, blood work and dietitian support. A lower medicine price with everything billed separately frequently costs more overall.

Availability in India

Availability of these products in India has fluctuated with global supply and regulatory timelines, and the position changes. A clinic should tell you what is currently accessible rather than promising something it cannot obtain.

This practical constraint sometimes matters more than the theoretical comparison. The best medicine you cannot get is not the best medicine for you.

Supply pressure is also why compounded and unbranded versions circulate. These are not quality-assured, the dose cannot be verified, and we do not prescribe them.

Ask directly what is available today and what happens if supply changes mid-treatment.

If you have type 2 diabetes

This substantially shapes the decision. Tirzepatide and semaglutide both have strong evidence for glucose control, and treating diabetes and weight together addresses the underlying driver rather than one symptom.

Products licensed for diabetes sit within diabetes care, and your existing medication will need review — insulin and sulfonylurea doses frequently require reducing.

Where diabetes is present, the choice is generally made by your treating physician in coordination with weight management rather than independently.

Some insurance policies also treat the position differently where diabetes is the primary diagnosis.

If you have PCOS

Insulin resistance drives much of the weight gain in PCOS, so the glucose-handling effect matters alongside appetite reduction.

Fertility is a specific consideration: weight loss can restore ovulation, and these medicines are not used in pregnancy. Contraception and conception timing must be discussed before starting, not after.

Metformin remains appropriate for many women with PCOS, is considerably cheaper and has a long safety record. It is sometimes used alongside.

The right answer depends on your BMI, metabolic markers and whether pregnancy is a near-term goal.

When an injection is not the right route at all

At a BMI of 40 and above, or 35 and above with serious weight-related disease, bariatric surgery produces substantially larger and more durable results, and frequently improves diabetes, sleep apnoea and blood pressure.

For patients wanting a defined, time-limited intervention without surgery, the swallowable gastric balloon occupies stomach volume for around sixteen weeks with no anaesthesia or endoscopy.

For patients below the treatment threshold, dietitian-led weight management is the appropriate route, and prescribing an injectable would not be.

A clinic offering only injections cannot give you this comparison honestly. That is a reason to ask what else they offer.

The questions that actually decide it

Which molecule do you recommend for me specifically, and why? What dose do you expect I will need, and what will that cost per month? What is available right now?

What happens if I do not tolerate it? Can I switch? What is included beyond the medicine? What is the plan for stopping?

How will you monitor me, and how often? Who do I contact outside clinic hours if something concerns me?

A clinician who answers these clearly is giving you what you need to decide. One who cannot is not.

Our position

We offer four routes — injectable programmes, the Allurion balloon, bariatric surgery and dietitian-led management — which means we can recommend the least invasive option that will realistically work rather than the only one we sell.

Sometimes that means telling a patient an injection is unlikely to be enough for their BMI. Sometimes it means telling them no treatment is appropriate yet.

The medicine with the best trial average is not automatically the right one for you, and any clinic saying otherwise is selling rather than advising.

That assessment is what a consultation is for.

Frequently asked questions